* If you want to update the article please login/register
SURE-01 is a neoadjuvant phase 2, open-label, non-randomized, singlecohort trial in patients with urothelial carcinoma of the bladder. Pathological complete response is the primary aim of the research, which is the aim of finding out if sacituzumab govitecan findings in pathological perfect response. During screening and imaging reaction, multiparametric bladder magnetic resonance imaging will be used to determine the local extent of bladder tumor, CT scan, 18F-fluorodeoxyglucose positron emission tomography /CT scan, and determining response will be done. On days 1, 8, and every 21-day cycle, eligible patients will receive neoadjuvant therapy: sacituzumab govitecan IV. Within four weeks of the last dose of study drug, surgery will be scheduled at the time of study participation, which will be completed at the time of study inclusion.
Source link: https://clinicaltrials.gov/ct2/show/NCT05226117
Hypothesis 2: IN ketamine will cause improvement in depressive symptoms, suicidal ideation, and quality of life in patients with URD who did not respond to or tolerate an acute course of convulsive therapy Hypothesis 2: IN ketamine will be safe and well tolerated in patients with URD who did not respond to or tolerate an acute course of convulsive therapy Hypothesis 2: IN ketamine will cause improvement in depressive symptoms, respiration, and quality of life hypocrita hypothese hypotical inhibition.
Source link: https://clinicaltrials.gov/ct2/show/NCT05137938
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions